Love Pharma (CSE:LUV) Co said its wholly-owned subsidiary MicroDoz Therapy’s sponsored trial testing the effectiveness of psilocybin in cannabis use disorder to be conducted at the Johns Hopkins Center for Psychedelic and Consciousness Research is advancing toward launch later in 2022.
The company’s proposed study timeline has final regulatory approval and the hiring of a study coordinator set for October to November, initial patient recruitment slated for December to January, and patient treatment completed by 1Q, 2024, with follow-ups in 2Q and 3Q, 2024.
The study will be led by Dr. Albert Garcia-Romeu, a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine, where he studies the effects of psychedelic drugs in humans, with a focus on psilocybin as an aid in the treatment of addiction.
READ: Love Pharma signs non-binding Letter of Intent to acquire Naltrexone Therapeutics
According to Love, the pilot trial will serve as a foundation to advance the research to larger-scale trials and drive future licensing and commercializing opportunities.
"Love is actively working to identify and assess biotechnology and pharmaceutical solutions to address addiction, with intent to grow its pharmaceutical presence in the underserved addiction treatment market,” Love Pharma (CSE:LUV) CEO Zach Stadnyk told investors in a press release.
"Since acquiring MicroDoz, the Love team has worked diligently to design and prepare to launch this comprehensive study relating to the potential of psilocybin-assisted treatment for cannabis use disorder, and we are excited to advance this initiative.”
Love Pharma (CSE:LUV) was founded in 2020 with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie